Lateralization on neuroimaging does not differentiate frontotemporal lobar degeneration from Alzheimer's disease.
Lateralization on neuroimaging was compared in cases of frontotemporal lobar degeneration (FTLD; n = 10) and cases of definite Alzheimer's disease (AD; n = 17). All of the cases were pathologically confirmed and semi-quantitative and statistical parametric mapping methods were employed. Seven of the 10 FTLD cases had lateralization on at least one neuroimaging modality: single photon emission computerized tomography (SPECT), MRI, or CT. All 6/6 FTLD cases with SPECT showed lateralization. MRI results generally agreed with SPECT findings. Three of 4 FTLD cases had lateralized atrophy on CT. For the AD cases, 10/17 SPECTs, 2/7 MRIs, and 1/9 CTs showed lateralized findings. Of the neuroimaging modalities utilized, SPECT was the most sensitive in detecting lateralization.
Lipton
Anne M
AM
Alzheimer's Disease Centers at The University of Texas Southwestern Medical Center, Dallas, Tex, USA. anne.lipton@UTSouthwestern.edu
Benavides
Raul
R
Hynan
Linda S
LS
Bonte
Frederick J
FJ
Harris
Thomas S
TS
White
Charles L
CL
Bigio
Eileen H
EH
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000503:physiopathology / Q000523:psychology*; D002560:Cerebrovascular Circulation; D003704:Dementia / Q000175:diagnosis* / Q000503:physiopathology / Q000523:psychology*; D003937:Diagnosis, Differential; D004292:Dominance, Cerebral; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime